DK1849470T4 - Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor - Google Patents

Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor Download PDF

Info

Publication number
DK1849470T4
DK1849470T4 DK06712292.9T DK06712292T DK1849470T4 DK 1849470 T4 DK1849470 T4 DK 1849470T4 DK 06712292 T DK06712292 T DK 06712292T DK 1849470 T4 DK1849470 T4 DK 1849470T4
Authority
DK
Denmark
Prior art keywords
alpha
trifluorthymidin
indeholder
cancerlægemiddel
thymidin
Prior art date
Application number
DK06712292.9T
Other languages
Danish (da)
English (en)
Other versions
DK1849470T3 (en
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1849470(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1849470T3 publication Critical patent/DK1849470T3/en
Publication of DK1849470T4 publication Critical patent/DK1849470T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06712292.9T 2005-01-26 2006-01-25 Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor DK1849470T4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
DK1849470T3 DK1849470T3 (en) 2017-08-14
DK1849470T4 true DK1849470T4 (en) 2024-04-02

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06712292.9T DK1849470T4 (en) 2005-01-26 2006-01-25 Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Country Status (21)

Country Link
EP (1) EP1849470B2 (enExample)
JP (1) JP5576591B2 (enExample)
KR (1) KR101468216B1 (enExample)
AU (1) AU2006209547C1 (enExample)
BE (1) BE2017C028I2 (enExample)
CA (1) CA2594713A1 (enExample)
CY (2) CY2017029I2 (enExample)
DK (1) DK1849470T4 (enExample)
ES (1) ES2630002T5 (enExample)
FI (1) FI1849470T4 (enExample)
FR (1) FR17C1028I2 (enExample)
HU (2) HUE033306T2 (enExample)
LT (2) LT1849470T (enExample)
LU (1) LUC00036I2 (enExample)
NL (1) NL300889I2 (enExample)
PL (1) PL1849470T5 (enExample)
PT (1) PT1849470T (enExample)
RU (1) RU2394581C2 (enExample)
SI (1) SI1849470T2 (enExample)
TW (1) TWI362265B (enExample)
WO (1) WO2006080327A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
SI1849470T2 (sl) 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
NZ588863A (en) 2008-05-09 2012-08-31 Gruenenthal Chemie Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
ES2718688T3 (es) 2009-07-22 2019-07-03 Gruenenthal Gmbh Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
NO2736497T3 (enExample) 2011-07-29 2018-01-20
ES2659264T3 (es) * 2011-08-16 2018-03-14 Taiho Pharmaceutical Co., Ltd. Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014157444A1 (ja) * 2013-03-27 2014-10-02 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
EP2979701B1 (en) * 2013-03-27 2020-08-26 Taiho Pharmaceutical Co., Ltd. Antitumor agent including irinotecan hydrochloride hydrate
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
SMT202300167T1 (it) 2013-09-06 2023-07-20 Taiho Pharmaceutical Co Ltd Agente antitumorale e potenziatore dell’effetto antitumorale
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
TWI791430B (zh) * 2016-02-05 2023-02-11 日商大鵬藥品工業股份有限公司 針對具有重度腎功能障礙之癌症患者之治療方法
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681321B2 (en) 1995-03-29 1997-08-21 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
AU699728B2 (en) * 1996-09-24 1998-12-10 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
SI1849470T2 (sl) 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Also Published As

Publication number Publication date
PL1849470T5 (pl) 2024-06-10
EP1849470A1 (en) 2007-10-31
CY2017029I1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
NL300889I1 (nl) 2017-08-14
RU2007132181A (ru) 2009-03-10
SI1849470T1 (sl) 2017-10-30
KR101468216B1 (ko) 2014-12-03
HUS1700032I1 (hu) 2017-09-28
EP1849470A4 (en) 2010-12-08
LT1849470T (lt) 2017-07-25
LUC00036I2 (enExample) 2017-12-01
EP1849470B2 (en) 2024-03-20
LTC1849470I2 (lt) 2019-10-25
CY2017029I2 (el) 2018-02-14
JP5576591B2 (ja) 2014-08-20
NL300889I2 (nl) 2018-01-16
FR17C1028I2 (fr) 2018-11-02
AU2006209547B2 (en) 2011-05-26
CA2594713A1 (en) 2006-08-03
CY1119393T1 (el) 2018-02-14
JPWO2006080327A1 (ja) 2008-06-19
HUE033306T2 (hu) 2017-11-28
ES2630002T3 (es) 2017-08-17
ES2630002T5 (es) 2024-09-19
TW200637562A (en) 2006-11-01
WO2006080327A1 (ja) 2006-08-03
LTPA2017024I1 (lt) 2017-08-10
PL1849470T3 (pl) 2017-11-30
AU2006209547C1 (en) 2022-04-07
PT1849470T (pt) 2017-09-22
TWI362265B (en) 2012-04-21
FI1849470T4 (fi) 2024-03-22
RU2394581C2 (ru) 2010-07-20
DK1849470T3 (en) 2017-08-14
FR17C1028I1 (enExample) 2017-09-29
AU2006209547A1 (en) 2006-08-03
BE2017C028I2 (enExample) 2025-09-10
LUC00036I1 (enExample) 2017-10-02
KR20070104559A (ko) 2007-10-26
SI1849470T2 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
DK1849470T4 (en) Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
AP2204A (en) 4-phenylamino-quinazolin-6-yl-amides.
ATE503759T1 (de) 7-ä2-ä4-(6-fluor-3-methyl-1,2-benzisoxazol-5-yl - 1-piperazinylüethylü-2-(1-propinyl)-7h-pyrazolo
PL1969815T1 (pl) Układ do korzystnie mobilnego użytkowania systemu ERP i dalszych aplikacji
EP1844567A4 (en) PASSWORDS
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
AP2850A (en) Selective havester
GB0506800D0 (en) New uses
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
HU0500500D0 (en) Ball for moving, used for general purposes
GB0503644D0 (en) Catstep I
GB0522528D0 (en) PPJS (peeJays) promotional-paperweigh-jambs
GB0502736D0 (en) Demopod (studiopod)
GB0522257D0 (en) H-rtm-roha(c)
GB0523210D0 (en) Blokbusta, heatbusta & trappa (variations on common principle)
GB0521911D0 (en) Alpha zetic
GB2440780B (en) The rula
AU2005900030A0 (en) Glowbal, Glowves, Moonstik
GB0500851D0 (en) C.f.m.
AP2005003379A0 (en) Lamp.
GB0526628D0 (en) C.I. Max
GB0509859D0 (en) VirtualTrolley.Com
ZAA200500720S (en) Retaining elements